106 related articles for article (PubMed ID: 12377645)
21. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
[TBL] [Abstract][Full Text] [Related]
22. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
[TBL] [Abstract][Full Text] [Related]
23. Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.
Rivera E; Chang JC; Semiglazov V; Burdaeva O; Kirby MG; Spector T
Clin Breast Cancer; 2014 Feb; 14(1):26-30. PubMed ID: 24183612
[TBL] [Abstract][Full Text] [Related]
24. A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies.
Yip D; Karapetis C; Strickland AH; Steer C; Holford C; Knight S; Harper P
Ann Oncol; 2003 Jun; 14(6):864-6. PubMed ID: 12796023
[TBL] [Abstract][Full Text] [Related]
25. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.
Ducreux M; Rougier P; Pignon JP; Douillard JY; Seitz JF; Bugat R; Bosset JF; Merouche Y; Raoul JL; Ychou M; Adenis A; Berthault-Cvitkovic F; Luboinski M;
Ann Oncol; 2002 Aug; 13(8):1185-91. PubMed ID: 12181240
[TBL] [Abstract][Full Text] [Related]
26. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Schilsky RL; Kindler HL
Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
[TBL] [Abstract][Full Text] [Related]
27. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
[TBL] [Abstract][Full Text] [Related]
28. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.
Saleem A; Yap J; Osman S; Brady F; Suttle B; Lucas SV; Jones T; Price PM; Aboagye EO
Lancet; 2000 Jun; 355(9221):2125-31. PubMed ID: 10902627
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer.
Skovsgaard T; Davidson NG; Piccart MJ; Richel DJ; Bonneterre J; Cirkel DT; Barton CM;
Ann Oncol; 2001 Sep; 12(9):1255-7. PubMed ID: 11697836
[TBL] [Abstract][Full Text] [Related]
30. Oral eniluracil/5-FU for advanced colon and breast carcinomas.
Benson AB
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):57-63; discussion 64. PubMed ID: 11219979
[TBL] [Abstract][Full Text] [Related]
31. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
32. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
Paff MT; Baccanari DP; Davis ST; Cao S; Tansik RL; Rustum YM; Spector T
Invest New Drugs; 2000 Nov; 18(4):365-71. PubMed ID: 11081572
[TBL] [Abstract][Full Text] [Related]
33. Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.
Leichman CG; Chansky K; Macdonald JS; Doukas MA; Budd GT; Giguere JK; Abbruzzese JL;
Invest New Drugs; 2002 Nov; 20(4):419-24. PubMed ID: 12448660
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
Llovet JM; Ruff P; Tassopoulos N; Castells L; Bruix J; El-Hariry I; Peachey M
Eur J Cancer; 2001 Jul; 37(11):1352-8. PubMed ID: 11435064
[TBL] [Abstract][Full Text] [Related]
35. A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil.
Spector T; Cao S
Clin Colorectal Cancer; 2010 Jan; 9(1):52-4. PubMed ID: 20100689
[TBL] [Abstract][Full Text] [Related]
36. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Baker SD; Khor SP; Adjei AA; Doucette M; Spector T; Donehower RC; Grochow LB; Sartorius SE; Noe DA; Hohneker JA; Rowinsky EK
J Clin Oncol; 1996 Dec; 14(12):3085-96. PubMed ID: 8955653
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
Sparano JA; Lipsitz S; Wadler S; Hansen R; Bushunow PW; Kirkwood J; Flynn PJ; Dutcher JP; Benson AB
Am J Clin Oncol; 1996 Dec; 19(6):546-51. PubMed ID: 8931668
[TBL] [Abstract][Full Text] [Related]
39. A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
Knowling M; Browman G; Siu L; Khoo K; Cooke A; Tannock I; Klaassen D; Cripps C; Goss G; Matthews S; Clarke R; Seymour L
Ann Oncol; 2001 Jul; 12(7):919-22. PubMed ID: 11521795
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
Morgan-Meadows S; Thomas JP; Mulkerin D; Berlin JD; Bailey H; Binger K; Volkman J; Alberti D; Feierabend C; Marrocha R; Arzoomanian RZ; Wilding G
Invest New Drugs; 2002 Nov; 20(4):377-82. PubMed ID: 12448654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
